Currently PD-L1 expression is only mandatory for the prescription of pembrolizumab, which is indicated as first-line treatment if ≥ 50% of tumor cells are positive for PD-L1, and as second-line therapy if PD-L1 expression is found in >1% tumor cells (3, 4). The gene discussed is CD274; the disease is neoplasm.